Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...
Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic...
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark...
OMB APPROVAL OMB Number: 3235-0145 Expires: October 31,2002 Estimated average burden hours per response 14.90 UNITED STATES SECURITIES AND...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESS Effective Date: December 22, 2009...
As filed with the Securities and Exchange Commission on December 22, 2009 Registration Statement No. 333-123017 ...
As filed with the Securities and Exchange Commission on December 22, 2009 Registration Statement No. 333-153533 ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or...
Company also Announces Timing and Plans to Voluntarily Delist from the Nasdaq Capital Market and Initiate Dissolution Process EMERYVILLE, Calif...
Board of Directors Declares Extraordinary Dividend of $0.75 per share EMERYVILLE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Neurobiological...
EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced today it has submitted...
EMERYVILLE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced today that, on...
EMERYVILLE, Calif., Sept. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. announced today that its financial statements for the...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관